Testing effectiveness (Phase 2)Ended earlyNCT02573935What this trial is testingClarithromycin in Multiple Myeloma Induction TherapyWho this might be right forMultiple Myeloma Henrik Gregersen 58
Large-scale testing (Phase 3)Study completedNCT00934154What this trial is testingMelphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Cigdem Sahinbas YILMAZ 122
Large-scale testing (Phase 3)UnknownNCT01685814What this trial is testingLenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide MaintenanceWho this might be right forPreviously Untreated Symptomatic Multiple Myeloma Wuerzburg University Hospital 406
Large-scale testing (Phase 3)Looking for participantsNCT07095452What this trial is testingAssess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantWho this might be right forMultiple Myeloma AbbVie 680
Large-scale testing (Phase 3)Study completedNCT00205764What this trial is testingTandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance TherapyWho this might be right forMultiple Myeloma Austrian Forum Against Cancer 212
Early research (Phase 1)Study completedNCT01038388What this trial is testingThe Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma Emory University 30
Early research (Phase 1)Looking for participantsNCT07477587What this trial is testingCompare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma (MM) Shanghai Henlius Biotech 258
Testing effectiveness (Phase 2)WithdrawnNCT03785184What this trial is testingVenetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWho this might be right forMultiple Myeloma AbbVie
Early research (Phase 1)UnknownNCT04309084What this trial is testingNatural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaWho this might be right forMultiple MyelomaNeoplasm, Plasma CellNeoplasms by Histologic Type+17 more Celularity Incorporated 29
Testing effectiveness (Phase 2)Study completedNCT02685826What this trial is testingDurvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma Celgene 56
Testing effectiveness (Phase 2)UnknownNCT00378755What this trial is testingSequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMMWho this might be right forMultiple Myeloma Korean Multiple Myeloma Working Party 62
Testing effectiveness (Phase 2)Study completedNCT01718743What this trial is testingIxazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWho this might be right forHematopoietic Cell Transplantation RecipientPlasma Cell Myeloma M.D. Anderson Cancer Center 64
Testing effectiveness (Phase 2)UnknownNCT01114048What this trial is testingEarly Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Chonnam National University Hospital 78
Testing effectiveness (Phase 2)Study completedNCT00566098What this trial is testingActivated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26
Large-scale testing (Phase 3)Study completedNCT00033332What this trial is testingDexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02217163What this trial is testingCarfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaWho this might be right forMultiple Myeloma Singapore General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03012880What this trial is testingIxazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaWho this might be right forPlasma Cell Myeloma Mayo Clinic 80
Not applicableNot Yet RecruitingNCT07823959What this trial is testingCBC-Based Inflammatory Indices in Newly Diagnosed Multiple MyelomaWho this might be right forMultiple Myeloma Assiut University 60
Large-scale testing (Phase 3)Looking for participantsNCT05558319What this trial is testingNDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideWho this might be right forNewly Diagnosed Multiple Myeloma PETHEMA Foundation 480
Large-scale testing (Phase 3)Active Not RecruitingNCT03729804What this trial is testingCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Who this might be right forMultiple Myeloma University of Chicago 250